DelveInsight's "Alpha- Antitrypsin Deficiency - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Alpha- Antitrypsin Deficiency epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2027

Alpha- Antitrypsin Deficiency Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Alpha- Antitrypsin Deficiency in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Alpha- Antitrypsin Deficiency outlook. It also includes the explanation of changing trends of epidemiology outlining the Alpha- Antitrypsin Deficiency scenario.

Alpha- Antitrypsin Deficiency Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Alpha- Antitrypsin Deficiency thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Alpha- Antitrypsin Deficiency explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Alpha- Antitrypsin Deficiency Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Alpha- Antitrypsin Deficiency

Key assessments
• Patient Segmentation in Alpha- Antitrypsin Deficiency
• Alpha- Antitrypsin Deficiency Risk & Burden
• Factors driving growth in a specific Alpha- Antitrypsin Deficiency patient population